Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
A comparative analysis of Patient-Reported Expanded Disability Status Scale tools.
Purine-crosslinked injectable chitosan sponges promote oligodendrocyte progenitor cells' attachment and differentiation.
Autologous hematopoietic SCT normalizes miR-16, -155 and -142-3p expression in multiple sclerosis patients.
A double-blind, placebo-controlled trial of adding erythropoietin to intravenous methylprednisolone for the treatment of unilateral acute optic neuritis of unknown or demyelinative origin.
[Contrast agents in MRI-diagnosis of multiple sclerosis].
Multiple sclerosis decreases explicit counterfactual processing and risk taking in decision making.
The psychosocial difficulties in brain disorders that explain short term changes in health outcomes.
International Pediatric MS Study Group Clinical Trials Summit: Meeting report.
Revisiting the management of fatigue in multiple sclerosis in the context of rehabilitation: a narrative review of current evidence.
Autonomic dysfunction in multiple sclerosis.
Interpreting therapeutic effect in multiple sclerosis via MRI contrast enhancing lesions: now you see them, now you don't.
A Comparison of Supervised Machine Learning Algorithms and Feature Vectors for MS Lesion Segmentation Using Multimodal Structural MRI.
Statins as immunomodulators: comparison with interferon-beta 1b in MS.
Angiotensin IV is Induced in Experimental Autoimmune Encephalomyelitis but Fails to Influence the Disease.
[Immunomodulatory properties of stem mesenchymal cells in autoimmune diseases.]
Oligodendrocyte progenitor cells: the ever mitotic cells of the CNS.
Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients.
Gait disorders in multiple sclerosis.
Monoclonal Antibodies in Treatment of Multiple Sclerosis.
[Impact of physical activity level on alexithymia and coping strategies in an over-40 multiple sclerosis population: A pilot study.]
Off-pump coronary surgery in a patient with multiple sclerosis.
Diagnosis and classification of autoimmune optic neuropathy.
Use of the PRIMUS scale to assess quality of life in a Spanish population of multiple sclerosis patients.
Therapy optimization: a new model for managing high-cost biologics.
Association of SNPs of CD40 Gene with Multiple Sclerosis in Russians.
Pages
« first
‹ previous
…
350
351
352
353
354
355
356
357
358
…
next ›
last »